Trastuzumab-Related Cardiac Dysfunction

Restricted access

The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity. The long-term significance of these events, isolating known cardiotoxic effects of anthracyclines from those of trastuzumab, and the appropriateness of referring to trastuzumab-related cardiotoxicity as reversible rather than responsive to trastuzumab withdrawal and heart failure medical therapy, are issues that continue to be debated. This article provides an overview of the available cardiac safety data from the major trastuzumab clinical trials in breast cancer, highlighting areas of ongoing controversy. Important recent data documenting the occurrence and prognostic use of cardiac troponin I elevations among patients treated with trastuzumab are placed into context with the mechanistic insight these data provide and the implications for clinical practice today.

Correspondence: Melinda L. Telli, MD, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826. E-mail: mtelli@stanford.edu
  • 1.

    Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 2.

    Slamon DJ, Eiermann W, Robert N, Pienkowski T. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5.

    • Search Google Scholar
    • Export Citation
  • 3.

    Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 4.

    Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 5.

    Seidman A, Hudis C, Pierri MK. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:12151221.

  • 6.

    Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:35253533.

    • Search Google Scholar
    • Export Citation
  • 7.

    Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 8.

    Spielmann M, Roche H, Delozier T. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:61296134.

    • Search Google Scholar
    • Export Citation
  • 9.

    Tan-Chiu E, Yothers G, Romond E. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 10.

    Joensuu H, Bono P, Kataja V. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:56855692.

    • Search Google Scholar
    • Export Citation
  • 11.

    Slamon DJ, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC->T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract]. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas.

    • Search Google Scholar
    • Export Citation
  • 12.

    Perez EA, Suman VJ, Davidson NE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:12311238.

    • Search Google Scholar
    • Export Citation
  • 13.

    Procter M, Suter TM, de Azambuja E. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:34223428.

    • Search Google Scholar
    • Export Citation
  • 14.

    Suter TM, Procter M, van Veldhuisen DJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:38593865.

    • Search Google Scholar
    • Export Citation
  • 15.

    Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 2010;28:39013904.

    • Search Google Scholar
    • Export Citation
  • 16.

    Guarneri V, Lenihan DJ, Valero V. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:41074115.

    • Search Google Scholar
    • Export Citation
  • 17.

    Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710717.

  • 18.

    Cardinale D, Colombo A, Lamantia G. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213220.

    • Search Google Scholar
    • Export Citation
  • 19.

    Cardinale D, Colombo A, Torrisi R. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:39103916.

    • Search Google Scholar
    • Export Citation
  • 20.

    Anderson JL, Adams CD, Antman EM. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007;116:e148304.

    • Search Google Scholar
    • Export Citation
  • 21.

    Hunt SA, Abraham WT, Chin MH. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force. Circulation 2005;112:e154235.

    • Search Google Scholar
    • Export Citation
  • 22.

    Herceptin. Full prescribing information. Available at: www.herceptin.com. Accessed December 16, 2010.

  • 23.

    Ewer MS, Vooletich MT, Durand JB. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:78207826.

    • Search Google Scholar
    • Export Citation
  • 24.

    Rastogi P, Jeong J, Geyer CE. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) -> paclitaxel (T) vs. AC -> T with trastuzumab (H) [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract LBA513.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 172 121 1
PDF Downloads 43 36 2
EPUB Downloads 0 0 0